Cytomegalovirus peptide vaccination in end-stage renal disease

Phase 1

Completed

• Conditions: Renal failure; Urological and Genital Diseases

• Registration Number: ISRCTN11842403
• Lead Sponsor: Renal Center Heidelberg

Brief Summary

2021 Results article in https://doi.org/10.3390/vaccines9020133 (added 06/06/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2016-08-31
• Study Start: 2017-04-28
• Last Update Posted: 20 June 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Aged 18 years and over
2. End-stage renal disease
3. CMV IgG seronegative
4. HLA-A2 expression positivity
5. Liver function tests below the threefold of the normal upper values
6. No active infection
7. Expected compliance
8. Provision of written informed consent

Exclusion Criteria

1. Prednisolone therapy >25 mg/d
2. Planned vaccination of other indication within the study period

Study & Design

• Study Type: Interventional
• Study Design: Not specified